ELECTROCORE, INC. (NASDAQ: ECOR) - PLANET MICROCAP TORONTO - ELECTROCORE INC

Financial Performance:

• Full-year 2025 revenue reached $19 million, with 50% compounded annual growth over the last five years.
• First half of 2026 revenue peaked at $32 million, establishing a revenue run rate of approximately $40 million.
• Gross profit margins expanded from the low 70s to the mid-to-high 80s.
• The business holds approximately $7.5 million in debt, with amortization scheduled to begin in March 2027.
• The TruVega wellness segment generated $2.4 million in 2024 and $5 million in 2025; the company prioritizes profitability over hyper-growth in this segment to achieve adjusted EBITDA positivity.
• Sales and marketing expenses currently comprise approximately 60% of revenue, with a strategic goal to reduce this to the 40-50% range.

Guidance and Future Outlook:

• Management targets achieving adjusted EBITDA positivity in the back half of 2027.
• Strategic focus includes accelerating revenue growth in the VA market and expanding into other federal segments (Federal Workers' Comp, TRICARE, active duty military) over the next two years.
• The company aims to capture 70% of the remaining VA headache market and expand penetration of the Quell Fibromyalgia product into accounts where it is not currently sold.
• Management views the current stock price (1.9–2x forward revenue) as significantly undervalued compared to the 10-year sector mean of roughly 4.5x forward revenue.
• The company is not actively seeking external capital at this time.

Business Segments and Product Lines:

• Prescription (Medical): "GammaCore" (non-invasive vagal nerve stimulation) targets primary headaches (migraine, cluster) with six FDA clearances; "Quell" (acquired via Neurometrics acquisition in May 2025) is the sole FDA-approved product for fibromyalgia, generating $1.3 million last quarter with 30% sequential growth.
• General Wellness: "TruVega" is a direct-to-consumer device for sleep and stress management; "TacStim" is a white-labeled, military-grade device for cognitive enhancement and human performance, co-developed with the Air Force Research Labs.
• New Filings: Filed a 510(k) application for the Quell device specifically for Chemotherapy-Induced Peripheral Neuropathy (CIPN), holding breakthrough designation for this indication which currently has no approved market treatments.
• Diversification: Secured formulary and contract status with Kaiser Permanente (12.5 million lives), the second-largest managed care system in the US.

Market and Competitive Landscape:

• Total Addressable Market (TAM): Approximately 600,000 headache patients and 9.5 million covered lives with PTSD within the VA system alone.
• Current penetration in the VA headache market is estimated at only 3%, representing significant growth potential.
• The VA and active-duty military represent a fragmented landscape of 170 unique customers and 1,300 locations.
• Quell is positioned as a monopoly for fibromyalgia treatment in the US, with a specific pipeline for active duty military personnel where deployment rates for fibromyalgia range from 2% to 11%.
• No pharmaceutical or medical devices currently exist specifically for the CIPN indication.

Risks and Challenges:

• High concentration risk: Approximately 70% of revenue is derived from the VA market.
• Operational inefficiency: Sales and marketing costs as a percentage of revenue remain elevated at 60% compared to industry norms.
• Commercialization hurdles: The need to navigate complex federal bureaucracy and red tape for active duty military prescriptions.
• Reimbursement and regulatory uncertainty associated with new indication filings (CIPN) and off-label usage (PTSD).

Management Commentary and Tone:

• The tone is confident and focused on a "turnaround" narrative, highlighting a clean cap table with no toxic warrants, ratchets, or anti-dilutes.
• Management emphasizes a shift from a "single product, single customer" perception to a diversified bioelectronic health platform with multiple "shots on net."
• Leadership introduced new commercial leadership, specifically Co-CEO Mike Fox, leveraging his 10-15 years of federal marketplace sales experience to drive expansion beyond the VA.
• The team stresses the systemic nature of vagal nerve stimulation (vagus nerve touches all visceral organs) as a key differentiator against "sniper" pharmaceutical approaches.

Analyst Questions and Answers:

• Break-even timeline: Management confirmed the target is adjusted EBITDA positivity in the second half of 2027.
• Capital needs: Confirmed the company is self-funding and not seeking external capital.
• VA Market Capture: Acknowledged the VA is fragmented (1,300 locations) but projects a significant dent in the market within two years using both GammaCore and Quell.
• CIPN Protocol: Clarified that the Quell device protocol for CIPN will be similar to fibromyalgia (preventative use throughout the day) pending approval.

Other Key Points:

• The company holds approximately 250 patents, primarily focused on cervical non-invasive vagal nerve stimulation and mobile app control.
• Over 30 investigator-initiated trials are ongoing, exploring indications from PTSD and mild traumatic brain injury to gastroparesis and stroke.
• Founder and CFO Dr. Tom Errico continues to exercise warrants and invest alongside the company.
• The "TacStim" device was developed to address military-specific needs, including drone pilot fatigue (using caffeine to stay awake followed by crashes) and language learning retention at the Defense Language Institute.
• The company recently upgraded its regulatory pathway for CIPN from "de novo" to "510(k)" based on FDA feedback, accelerating the approval timeline.